CELLISTI, Voi non potete evitare che gli UCCELLI del malugurio volino sulla vostra
-
INVESTIMENTO IN LENDING CROWDFUNDING SU WALLIANCE: 21 MESI E CEDOLE TRIMESTRALI
Su Walliance è aperto l’investimento in Lending “Padova, Residence Linea 4.0”. Durata 21 mesi; distribuzione del TAN in cedole trimestrali; restituzione del capitale alla scadenza del finanziamento.
Campagna di raccolta investimenti > 90%.
Ticket minimo € 500.
Per continuare a leggere visita questo LINK
eccellente
Utente Registrato
- Registrato
- 1/7/10
- Messaggi
- 604
- Punti reazioni
- 25
buongiorno sotto la neve,,se la FDA avesse bocciato sic et simpliciter il pixantrone,a quest'ora chissà quanti gufi si sarebbero già fatti vivi...ahhhhhh
eccellente
Utente Registrato
- Registrato
- 1/7/10
- Messaggi
- 604
- Punti reazioni
- 25
ciaoooooogufi?ndove...
PRESENTE
chissà quanta neve a trento....
forse piu' che a Venezia,,,,
saluti dalla bassa popolata da splendide fate bianche
ciaoooooo
chissà quanta neve a trento....
forse piu' che a Venezia,,,,
saluti dalla bassa popolata da splendide fate bianche
ti sembrera' strano ma qua non ha fatto un fiocco sti giorni
piu 8 gradi adesso.. il maltempo è tutto spostato da voi 
Vendi & Guadagna
Utente Registrato
- Registrato
- 7/5/10
- Messaggi
- 52
- Punti reazioni
- 2
'Ngiorno!
Tontolone
Utente Registrato
- Registrato
- 24/5/10
- Messaggi
- 4.814
- Punti reazioni
- 135
willydenny
Manovratori sveglia
- Registrato
- 25/1/07
- Messaggi
- 6.353
- Punti reazioni
- 234
Buongiorno a tutti , forse è anche un bene che la fda sposti la data , se va bene con l'EMEA.... la fda dovrà pensarci bene prima di esprimersi , ricordiamo che l'altra volta non l'ha neanche esaminato il pix , ora avrebbe il responso dell'emea ( speriamo positivo ) e le pressioni governative di non allontanare la ricerca privata coi suoi troppi no ai farmaci nuovi...
fiorentininoo
alea iacta est
- Registrato
- 25/11/07
- Messaggi
- 5.738
- Punti reazioni
- 130
FDA's Office of New Drugs Meets With Cell Therapeutics on its Appeal on Pixantrone
SEATTLE, March 3, 2011 /PRNewswire via COMTEX/ --
Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) today announced that it has met with officials of the FDA's Office of New Drugs ("OND") in Maryland and presented its arguments supporting the Company's belief that the data contained in its New Drug Application ("NDA") 22-481 support the conclusion that pixantrone is effective for its planned use.
"We appreciate OND's consideration of our appeal. While we understand disputes of this type are a challenging process, we felt compelled to seek this review based on the PIX301 results and lack of approved therapies for these patients with an unmet medical need. CTI is committed to the advancement of pixantrone," said James A. Bianco, M.D., CEO of CTI.
At the meeting, the OND requested additional analyses from the PIX301 Phase III clinical study. CTI intends to submit the requested information and expects that this will reset the time period for OND to provide its decision on the appeal. CTI anticipates a decision in the second quarter of 2011.
About Pixantrone
Pixantrone is a novel aza-anthracenedione that has distinct structural and physio-chemical properties that make its anti-tumor activity unique in this class of agents. Similar to anthracyclines, pixantrone inhibits Topo-isomerase II but unlike anthracyclines--rather than intercalation with DNA--pixantrone alkylates DNA--forming stable DNA adducts, with particular specificity for CpG rich, hyper-methylated sites. These structural differences resulted in significantly enhanced anti-lymphoma activity compared to doxorubicin in preclinical models. In addition, the structural motifs on anthracycline-like agents that are responsible for the generation of oxygen free radicals and the formation of toxic drug-metal complexes have also been modified in pixantrone to prevent the binding of iron and perpetuation of superoxide production--both of which are the putative mechanism for anthracycline induced acute cardiotoxicity. These novel pharmacologic differences may allow re-introduction of anthracycline like potency in the treatment of relapsed/refractory aggressive lymphoma without unacceptable rates of cardiotoxicity.
SEATTLE, March 3, 2011 /PRNewswire via COMTEX/ --
Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) today announced that it has met with officials of the FDA's Office of New Drugs ("OND") in Maryland and presented its arguments supporting the Company's belief that the data contained in its New Drug Application ("NDA") 22-481 support the conclusion that pixantrone is effective for its planned use.
"We appreciate OND's consideration of our appeal. While we understand disputes of this type are a challenging process, we felt compelled to seek this review based on the PIX301 results and lack of approved therapies for these patients with an unmet medical need. CTI is committed to the advancement of pixantrone," said James A. Bianco, M.D., CEO of CTI.
At the meeting, the OND requested additional analyses from the PIX301 Phase III clinical study. CTI intends to submit the requested information and expects that this will reset the time period for OND to provide its decision on the appeal. CTI anticipates a decision in the second quarter of 2011.
About Pixantrone
Pixantrone is a novel aza-anthracenedione that has distinct structural and physio-chemical properties that make its anti-tumor activity unique in this class of agents. Similar to anthracyclines, pixantrone inhibits Topo-isomerase II but unlike anthracyclines--rather than intercalation with DNA--pixantrone alkylates DNA--forming stable DNA adducts, with particular specificity for CpG rich, hyper-methylated sites. These structural differences resulted in significantly enhanced anti-lymphoma activity compared to doxorubicin in preclinical models. In addition, the structural motifs on anthracycline-like agents that are responsible for the generation of oxygen free radicals and the formation of toxic drug-metal complexes have also been modified in pixantrone to prevent the binding of iron and perpetuation of superoxide production--both of which are the putative mechanism for anthracycline induced acute cardiotoxicity. These novel pharmacologic differences may allow re-introduction of anthracycline like potency in the treatment of relapsed/refractory aggressive lymphoma without unacceptable rates of cardiotoxicity.
Tontolone
Utente Registrato
- Registrato
- 24/5/10
- Messaggi
- 4.814
- Punti reazioni
- 135
secondo me vola
stamane compro
magiceddy
Utente Registrato
- Registrato
- 24/6/09
- Messaggi
- 3.671
- Punti reazioni
- 77
secondo me vola
Quest'uomo è diabolico
